Cancer Therapy

Exelixis initiates phase I safety trial for XL784

Published in Cancer Weekly, July 15th, 2003

Exelixis, Inc., (EXEL) has initiated the phase I first-in-man safety trial for its proprietary small molecule anticancer compound XL784.

The phase I trial will be conducted at a single center and is expected to enroll approximately 70 healthy subjects in a dose-escalating study intended to explore the safety, pharmacokinetic, and pharmacodynamic merits of the compound following oral administration. The trial should be completed within a year. Concurrent with the phase I trial, Exelixis plans to explore the therapeutic utility of the compound in various animal models of disease outside of cancer, including renal and cardiovascular disease.

"XL784 is...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2003-07-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry